Receive our newsletter – data, insights and analysis delivered to you
November 7, 2013

Neopharm to market Prima BioMed’s ovarian cancer drug in Israel

Australia-based Prima BioMed (Prima) has granted an exclusive license to Neopharm Group (Neopharm) to market and sell CVac, its personalised immunocellular therapeutic product, in Israel and Palestine.

By admin-demo

Carcinoma

Australia-based Prima BioMed (Prima) has granted an exclusive license to Neopharm Group (Neopharm) to market and sell CVac, its personalised immunocellular therapeutic product, in Israel and Palestine.

CVac is currently under investigation for the treatment of epithelial ovarian cancer and the final agreement is scheduled for within 90 days.

As part of the deal, Neopharm will repay Prima for commercial manufacturing costs of CVac and later both the firms will share net profits from CVac sales in the licensed territory.

In addition, Prima will also receive small up-front and development milestone payments under the agreement.

Prima CEO Matthew Lehman said the first corporate partnership for CVac with Neopharm represents the company’s commercial potential to successfully develop cell based immunotherapies for cancer.

"Neopharm is among the largest and most substantial corporations operating across the Israeli healthcare sector," Lehman said.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

"Neopharm’s expertise and strengths in marketing of groundbreaking pharmaceuticals and biological therapies, and in particular oncology treatments, will enable us to successfully penetrate to the Israeli market."

"CVac is a vaccine therapy treatment for ovarian cancer sufferers that is administered post-surgery and post-chemotherapy to delay a relapse."

Neopharm chairman and CEO David Fuhrer said: "We see CVac as an excellent addition to our group’s growing portfolio of innovative products."

Prima BioMed’s personalised immunocellular therapy, CVac is a vaccine therapy treatment for ovarian cancer sufferers that is administered post-surgery and post-chemotherapy to delay a relapse and control the metastases of the cancer.

It is a cancer vaccine product consisting of an adjuvant, mannan, attached to a tumour cell surface protein, mucin 1 and is administered as intradermal injection.

CVac targets mucin 1 overexpressing cancer cells, and is currently in late-phase trials for the treatment of epithelial ovarian cancer in remission.

Prima develops personalised immunocellular therapeutic products for the treatment of cancer and leverages its technology and expertise to bring new treatment options to market for patients.


Image: Micrograph of serous carcinoma, a type of ovarian cancer, diagnosed in peritoneal fluid. Photo: courtesy of Nephron.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU